Research has identified how PD-L1 may be an important marker, with other studies recognizing an association of PD-L1 expression and response to targeted therapy in patients with NSCLC, making PD-L1 a potential prognostic factor for SCLC [33,34,35,36]. This evidence concerns the gene CD274 and small cell lung carcinoma.